COVID-19

COVID-19 vaccines: under evaluation

The European Medicines Agency (EMA) is evaluating potential COVID-19 vaccines to enable the distribution of promising vaccines in the European Union (EU) as soon as possible. 

COVID-19 vaccines under rolling review

EMA's Committee for Medicinal Products for Human Use (CHMP) is evaluating the following COVID-19 vaccines:

VaccineVaccine developerKey milestonesMore information
CVnCoVCureVac AG
Start of rolling review: 12/02/2021
NVX-CoV2373
Novavax CZ AS
Start of rolling review: 03/02/2021

For more information on the expedited evaluation procedure EMA is applying for COVID-19 vaccines, including the rolling review, see:

COVID-19 vaccines under conditional marketing authorisation evaluation

EMA's Committee for Medicinal Products for Human Use (CHMP) is evaluating the conditional marketing authorisation application of the following COVID-19 vaccines:

VaccineVaccine developerKey milestonesMore information
COVID-19 Vaccine Janssen (updated)
Janssen-Cilag International N.V.
Start of conditional marketing authorisation evaluation: 16/02/2021
 
Start of rolling review: 01/12/2020
 

For more information on the expedited evaluation procedure EMA is applying for COVID-19 vaccines, including the conditional marketing authorisation, see:

Topics

How useful was this page?

Add your rating
Average
4 ratings
2 ratings
2 ratings
6 ratings